Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer.

Oh SC, Park YY, Park ES, Lim JY, Kim SM, Kim SB, Kim J, Kim SC, Chu IS, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz S, Lee JS
Gut. 2012 61 (9): 1291-8

PMID: 21997556 · PMCID: PMC3419333 · DOI:10.1136/gutjnl-2011-300812

AIMS - Despite continual efforts to develop prognostic and predictive models of colorectal cancer by using clinicopathological and genetic parameters, a clinical test that can discriminate between patients with good or poor outcome after treatment has not been established. Thus, the authors aim to uncover subtypes of colorectal cancer that have distinct biological characteristics associated with prognosis and identify potential biomarkers that best reflect the biological and clinical characteristics of subtypes.

METHODS - Unsupervised hierarchical clustering analysis was applied to gene expression data from 177 patients with colorectal cancer to determine a prognostic gene expression signature. Validation of the signature was sought in two independent patient groups. The association between the signature and prognosis of patients was assessed by Kaplan-Meier plots, log-rank tests and the Cox model.

RESULTS - The authors identified a gene signature that was associated with overall survival and disease-free survival in 177 patients and validated in two independent cohorts of 213 patients. In multivariate analysis, the signature was an independent risk factor (HR 3.08; 95% CI 1.33 to 7.14; p=0.008 for overall survival). Subset analysis of patients with AJCC (American Joint Committee on Cancer) stage III cancer revealed that the signature can also identify the patients who have better outcome with adjuvant chemotherapy (CTX). Adjuvant chemotherapy significantly affected disease-free survival in patients in subtype B (3-year rate, 71.2% (CTX) vs 41.9% (no CTX); p=0.004). However, such benefit of adjuvant chemotherapy was not significant for patients in subtype A.

CONCLUSION - The gene signature is an independent predictor of response to chemotherapy and clinical outcome in patients with colorectal cancer.

MeSH Terms (20)

Adult Aged Aged, 80 and over Antineoplastic Agents Chemotherapy, Adjuvant Cluster Analysis Cohort Studies Colorectal Neoplasms Female Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Kaplan-Meier Estimate Male Middle Aged Prognosis Proportional Hazards Models Survival Rate Treatment Outcome Young Adult

Connections (2)

This publication is referenced by other Labnodes entities:

Links